Volagidemab

Volagidemab is a monoclonal antibody that targets the glucagon receptor. It is developed by REMD Biotherapeutics for type 1 and type 2 diabetes. A phase II trial did not meet its primary endpoint.

Research

A systematic review and meta-analysis of volagidemab, published in 2024, found it to be potentially beneficial in the treatment of type1 diabetes.